• Home
  •  / GlycoMimetics

GlycoMimetics

OverviewSuggest Edit

GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

TypePublic
Founded2003
HQRockville, MD, USMap
Websiteglycomimetics.com
View Jobs (1)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)50(+25%)
Job Openings1
Revenue (FY, 2020)$10.2 M(+54835%)
Share Price (Jun 2021)$2.8(-1%)
Cybersecurity ratingCMore

Key People/Management at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
Mark A. Goldberg

Mark A. Goldberg

Director
William Fogler

William Fogler

Senior Director, Preclinical Studies
Daniel M. Junius

Daniel M. Junius

Director
Patricia S. Andrews

Patricia S. Andrews

Director
Helen Thackray

Helen Thackray

Senior Vice President, Clinical Development, and Chief Medical Officer
Show more

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville
Rockville, MD, US (HQ)
9708 Medical Center Dr
Show all (1)

GlycoMimetics Financials and Metrics

GlycoMimetics Revenue

GlycoMimetics's revenue was reported to be $10.16 m in FY, 2020
USD

Revenue (Q1, 2021)

1.1m

Net income (Q1, 2021)

(14.3m)

EBIT (Q1, 2021)

(14.3m)

Market capitalization (11-Jun-2021)

141.7m

Closing stock price (11-Jun-2021)

2.8

Cash (31-Mar-2021)

132.5m

EV

11.9m
GlycoMimetics's current market capitalization is $141.7 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

15.0m20.1m18.5k10.2m

Revenue growth, %

34%(100%)

General and administrative expense

6.6m7.8m8.7m9.8m11.4m14.4m16.7m

R&D expense

19.6m25.1m23.3m24.1m40.1m47.0m44.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

15.0m20.0m18.5k9.0m1.0m1.1m

General and administrative expense

1.2m1.6m1.6m1.9m1.8m2.1m2.1m2.3m2.0m2.1m2.5m2.4m2.9m2.8m2.8m3.4m3.4m4.4m4.2m4.1m4.2m

R&D expense

3.9m5.4m5.1m5.2m7.8m5.0m5.5m5.8m5.9m5.9m5.7m5.8m9.0m9.3m9.7m11.8m10.7m12.7m9.9m10.7m11.1m

Operating expense total

5.1m7.0m6.7m7.1m9.6m7.2m7.6m8.1m7.9m8.0m8.2m8.2m11.9m12.1m12.5m15.1m14.1m17.1m14.1m14.7m15.3m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

55.2m46.8m40.0m123.9m209.9m158.2m137.0m

Accounts Receivable

13.6m102.0k413.1k186.0k2.1k

Prepaid Expenses

3.3m2.4m4.3m1.2m

Inventories

916.2k441.8k478.5k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

57.0m66.2m61.4m46.6m40.2m53.8m38.8m53.1m45.3m34.6m119.1m112.9m242.6m229.4m219.8m195.6m184.2m170.9m154.8m149.8m142.9m132.5m

Accounts Receivable

42.1k22.4k1.0k20.0m1.3k58.8k611.8k572.1k41.1k68.0k75.6k152.6k326.3k312.2k354.1k313.1k578.6k91.6k49.4k1.7k444.6k

Prepaid Expenses

719.0k881.7k587.8k777.1k534.9k718.2k683.4k1.4m1.2m697.1k502.2k1.0m3.5m3.5m2.6m2.8m2.3m3.9m2.1m3.5m2.8m1.2m

Current Assets

57.7m67.1m61.9m47.3m60.8m54.5m39.5m54.5m46.5m35.3m119.7m113.9m246.1m232.9m222.4m198.4m186.5m174.8m156.9m153.4m145.6m133.7m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.1m)(12.8m)(31.8m)(33.3m)(48.3m)(57.9m)(51.0m)

Depreciation and Amortization

158.7k191.5k190.5k263.5k275.1k279.2k270.8k

Inventories

1.7m474.4k(36.7k)

Accounts Payable

(270.9k)(309.8k)1.0m1.1m16.5k(1.2m)654.3k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(5.1m)2.9m(3.7m)(7.1m)3.3m(3.9m)(7.6m)(15.6m)(23.5m)(7.9m)(16.1m)(24.0m)(11.5m)(22.8m)(34.4m)(14.1m)(29.9m)(43.2m)(7.7m)(21.7m)(35.5m)(14.3m)

Depreciation and Amortization

34.6k73.5k114.3k44.2k90.5k142.4k47.2k93.9k139.7k54.3k123.9k194.0k68.8k138.3k206.8k70.4k141.6k211.4k68.2k135.9k202.4k68.1k

Accounts Payable

652.1k(672.7k)(561.2k)299.5k222.5k(240.9k)1.0m816.9k682.5k(1.1m)(990.1k)66.5k1.2m592.4k(2.0m)(832.6k)363.2k(1.3m)1.7m(70.9k)(362.0k)50.9k

Cash From Operating Activities

(2.6m)6.6m1.9m(8.7m)(14.8m)(1.3m)(9.2m)(16.3m)(23.8m)(9.1m)(15.2m)(21.4m)(10.2m)(23.3m)(33.4m)(14.3m)(25.7m)(39.2m)(3.5m)(18.1m)(29.6m)(14.1m)
show all
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

GlycoMimetics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

Learn more about our premium products
SecurityScorecard logo

GlycoMimetics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

GlycoMimetics Online and Social Media Presence

GlycoMimetics's Trends

Embed Graph

GlycoMimetics News and Updates

April 14, 2021

Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal

DUBLIN, April 14, 2021 /PRNewswire/ -- The "Disease Analysis: Acute Myeloid Leukemia (AML)" report has been added to ResearchAndMarkets.com's offering. AML is a type of heterogeneous hematological malignancy that originates from immature white blood cells (blasts) in the bone marrow,...
October 06, 2020

FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle cell disease in patients 18 years old and younger. This designation recognizes the significant n…
August 05, 2019

GlycoMimetics stock down 53% after Phase 3 trial failure

Shares of GlycoMimetics Inc. fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with Pfizer Inc. , did not meet primary or secondary endpoints. Shares of Pfizer were down 0.8% in premarket trade…
May 06, 2018

GlycoMimetics' (GLYC) CEO Rachel King on Q1 2018 Results - Earnings Call Transcript

April 04, 2018

GlycoMimetics: Buy This Dip

March 09, 2018

New Detailed Study on Anemia Drugs Market by Leading Key Players: GlycoMimetics, Mast Therapeutics, Fibrogen

Anemia Drugs Market Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday

GlycoMimetics Blogs

May 27, 2021

GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference

GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference Content Import Thu, 05/27/2021 - 19:08 GlycoMimetics to Present at Jefferies 2021 Virtual Healthcare Conference May 27, 2021 at 7:08 PM EDT This release is a backfill from a News Wire …
May 26, 2021

GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

Clinicians at Washington University in St. Louis Enroll Trial’s First Patient at Siteman Cancer Center ROCKVILLE, Md. --(BUSINESS WIRE)--May 26, 2021-- GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that clinicians at Washington University School of Medicine in St.
May 03, 2021

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021

GlycoMimetics continues to target year-end 2021 for completing enrollment of the Company-sponsored pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Enrollment in the Phase 2 portion of the NCI-sponsored Phase 2/3 registration trial evaluating
April 26, 2021

GlycoMimetics to Report First Quarter Financial Results on May 3, 2021

ROCKVILLE, Md. --(BUSINESS WIRE)--Apr. 26, 2021-- GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021 , at 8:30 a.m. ET . The dial-in number for the conference call is (844) 413-7154 for
April 10, 2021

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model Content Import Sat, 04/10/2021 - 09:00 GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Mod…
April 10, 2021

Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting

Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting Content Import Sat, 04/10/2021 - 09:00 Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting April 10, 2021 at 9:00 AM EDT …
Show more

 GlycoMimetics Frequently Asked Questions

  • When was GlycoMimetics founded?

    GlycoMimetics was founded in 2003.

  • Who are GlycoMimetics key executives?

    GlycoMimetics's key executives are Brian Hahn, Mark A. Goldberg and William Fogler.

  • How many employees does GlycoMimetics have?

    GlycoMimetics has 50 employees.

  • What is GlycoMimetics revenue?

    Latest GlycoMimetics annual revenue is $10.2 m.

  • What is GlycoMimetics revenue per employee?

    Latest GlycoMimetics revenue per employee is $203.3 k.

  • Who are GlycoMimetics competitors?

    Competitors of GlycoMimetics include DAVA Oncology, Actuate Therapeutics and Galecto.

  • Where is GlycoMimetics headquarters?

    GlycoMimetics headquarters is located at 9708 Medical Center Dr, Rockville.

  • Where are GlycoMimetics offices?

    GlycoMimetics has an office in Rockville.

  • How many offices does GlycoMimetics have?

    GlycoMimetics has 1 office.